Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2019, 28(1):21-25

Managing cardiotoxicity induced by chemotherapy in centers from low income countries

Rodríguez-Ramos MA, Fardales-Rodríguez R
Unidad de Cuidados Coronarios, Departamento Cardiología, Hospital General Universitario Camilo Cienfuegos, Sancti-Spirítus, Cuba

Cardiovascular diseases and cancer account for 60% of deaths in the Western world. They have common risk factors, such as obesity and diabetes, and are often found in the same patient. It is more common in a patient with tumour disease who develops cardiovascular involvement secondary to treatment with cytostatic or radiotherapy. A protocol of in-hospital management of cardiotoxicity induced by cytostatic is proposed with the objective of providing specialized care to patients with cancer and a history of cardiovascular disease or who develop cardiac complications during cancer therapy, in centres of low-income countries. Care and follow-up criteria are established; guidelines to identify patients who are at risk of developing cardiac dysfunction, and strategies are proposed to prevent or minimize the risk before, during and after the therapy. Finally, suggestions are presented to treat specific complications: ischemia, systemic embolism, more frequent arrhythmias, pulmonary and systemic hypertension.

Keywords: cardiotoxicity; chemotherapy; cardiovascular complications

Published: January 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rodríguez-Ramos, Fardales-Rodríguez R. Managing cardiotoxicity induced by chemotherapy in centers from low income countries. Cardiology Letters. 2019;28(1):21-25.
Download citation

References

  1. Teske AJ, Linschoten M, Kamphuis JAM, et al. Cardio-oncology: an overview on outpatient management and future developments. Neth Heart J. 2018 Nov 26:521-532. doi: 10.1007/s12471-0181148-7. Go to original source...
  2. Herrmann J, Loprinzi C, Ruddy K. Building a Cardio-oncohematology program. Curr Oncol Rep. 2018 Sep 10;20:81. Go to original source...
  3. Kostakou PM, Kouris NT, Kostopoulos VS, et al. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology. Heart Fail Rev. 2018 Aug 2. doi: 10.1007/s10741018-9731-y. Go to original source...
  4. Armanious MA, Mohammadi H, Khodor S, et al. Cardiovascular effects of radiation therapy. Curr Probl Cancer. 2018 Jul 42;433442. doi: 10.1016/j.currproblcancer.2018.05.008. Go to original source...
  5. Farmakis D, Mantzourani M, Filippatos G. Anthracycline-induced cardiomyopathy: secrets and lies. Eur J Heart Fail. 2018 May 20;907-909. doi: 10.1002/ejhf.1172. Go to original source...
  6. Naaktgeboren WR, Linschoten M, de Graeff A, et al Long-term cardiovascular health in adult cancer survivors. Maturitas. 2017;105:37-45. doi: 10.1016/j.maturitas.2017.05.014. Go to original source...
  7. Skubitz KM, Blaes AH, Konety SH, et al. Cardiac safety profile of patients receiving high cumulative doses of pegylatedliposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer Chemother Pharmacol. 2017 Oct 80:787-798. doi: 10.1007/s00280-017-3420-8. Go to original source...
  8. Agmon Nardi I, Iakobishvili Z. Cardiovascular risk in cancer survivors. Curr Treat Options Cardiovasc Med. 2018 Apr 28;20:47. doi: 10.1007/s11936-018-0645-8. Go to original source...
  9. Narayan V, Ky B. Common cardiovascular complications of cancer therapy: Epidemiology, risk prediction, and prevention. Annu Rev Med. 2018 Jan 29;69:97-111. doi: 10.1146/annurevmed-041316-090622. Go to original source...
  10. Koutsoukis A, Ntalianis A, Repasos E, et al. Cardio-oncology: A focus on cardiotoxicity. Eur Cardiol. 2018 Aug 13;64-69. doi Go to original source...
  11. 15420/ecr.2017:17:2. Go to original source...
  12. Tajiri K, Aonuma K, Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017 Aug 1;47:678-682. doi: 10.1093/jjco/hyx068. Go to original source...
  13. Current Status of Cardio-Oncology in Spain: A National Multidisciplinary Survey. Martín-García A, Mitroi C, García Sanz R, Santaballa Bertrán A, Arenas M: Rev Esp Cardiol (Engl Ed). 2017; Dec 6. pii: S1885-5857(17)30515-7. doi: 10.1016/j.rec.2017.11.002. Go to original source...
  14. Fiuza M, Ribeiro L, Magalhaes A, et al. Organization and implementation of a cardio-oncology Program. Rev Port Cardiol. 2016;35:485-494. Go to original source...
  15. Lancellotti P, Suter TM, López-Fernández T, et al. Cardio-oncology services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council. Eur Heart J. 2018 Aug 6. doi: 10.1093/eurheartj/ehy453. Go to original source...
  16. Guha A, Armanious M, Fradley MG. Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med. 2018 Jun 8. pii: S1050-1738(18)300860. doi: 10.1016/j.tcm.2018.06.001. Go to original source...
  17. Ewer S. Guest Editorial: Is cardio-oncology ready for algorithms? Eur Cardiol. 2018 Aug 13:62-63. doi: 10.15420/ecr.2018.13.1.GE2. Go to original source...
  18. Snipelisky D, Jae-Yoon P, Lerman A, et al. How to develop a cardiooncology clinic. Heart Failure Clin 2017; 13: 347-359. http://dx.doi.org/10.1016/j.hfc.2016.12.011. Go to original source...
  19. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35:893-911. Go to original source...
  20. Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and management of patients with heart disease and cancer: cardiooncology. Mayo Clin Proc 2014;89:1287-1306. Go to original source...
  21. Tilemann LM, Heckmann MB, Katus HA, et al. Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome. Clin Res Cardiol. 2018 Apr;107:271-280. doi: 10.1007/s00392-018-1202-x. Go to original source...
  22. Farmakis D, Keramida K, Filippatos G. How to build a cardiooncology service? Eur J Heart Fail. 2018 Oct 17. doi: 10.1002/ejhf.1336. Go to original source...
  23. Marangou J, Redfern A, Haddad T, et al Heart failure following oncological treatment. Curr Opin Cardiol. 2018 Mar 33;237244. doi: 10.1097/HCO.0000000000000488 Go to original source...
  24. Gulati G, Heck SL, Røsjø H, et al. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers during Anthracycline Therapy in Breast Cancer Patients: Results from the PRADA (Prevention of Cardiac Dysfunction during Adjuvant Breast Cancer Therapy) Study. J Am Heart Assoc. 2017 Nov 8;6. pii: e006513. doi: 10.1161/JAHA.117.006513. Go to original source...
  25. Payne DL, Nohria A. Prevention of chemotherapy induced cardiomyopathy. Curr Heart Fail Rep. 2017 Oct 14:398-403. doi: 10.1007/s11897-017-0353-9. Go to original source...
  26. Kim H, Chung WB, Cho KI, et al. Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography. J Cardiovasc Ultrasound. 2018 Mar 26;1-25. doi: 10.4250/jcu.2018.26.1.1. Go to original source...
  27. The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology: 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J 2016;37:2768-2801.
  28. Banke A, Fosbøl EL, Møller JE, et al. Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. Eur J Heart Fail. 2018 Oct 20;1447-1453. doi: 10.1002/ejhf.1168. Go to original source...
  29. Ameri P, Canepa M, Anker MS, et al. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail. 2018 May 20;879-887. doi: 10.1002/ejhf.1165. Go to original source...
  30. Scott JM, Nilsen TS, Gupta D, et al. Exercise therapy and cardiovascular toxicity in cancer. Circulation. 2018;137:1176-1191. DOI: 10.1161/CIRCULATIONAHA.117.024671 Go to original source...
  31. Yetis Sayin B, Oto MA. Acute coronary syndrome in cancer patients. Am J Cardiovasc Drugs. 2018 Jun;22. doi: 10.1007/s40256-0180286-z. Go to original source...
  32. Hui-Ming Ch, Moudgil R, Scarabelli T, et al. Cardiovascular complications of cancer therapy. Best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol 2017;70:2536-2551. Go to original source...
  33. Cheng F, Loscalzo J. Pulmonary comorbidity in lung cancer. Trends Mol Med. 2018 Mar 24;239-241. doi: 10.1016/j.molmed.2018.01.005. Go to original source...
  34. Ghosh AK, Crake T, Manisty C, et al. Pericardial disease in cancer patients. Curr Treat Options Cardiovasc Med. 2018 Jun 23;20:60. doi: 10.1007/s11936-018-0654-7. Go to original source...
  35. Darocha S, Wilk M, Walaszkowska-Czyż A, et al. Determinants of survival after emergency intrapericardial cisplatin treatment in cancer patients with recurrent hemodynamic instability after pericardiocentesis. In Vivo. 2018 Mar-Apr 32;373-379. Go to original source...
  36. Steingart RM, Chandrashekhar Y, et al. Imaging in cardiooncology: Where are we and where should we be going? JACC Cardiovasc Imaging. 2018 Aug 11:1209-1211. doi: 10.1016/j.jcmg.2018.07.001. Go to original source...
  37. Tuzovic M, Herrmann J, Iliescu C, et al. Arterial thrombosis in patients with cancer. Curr Treat Options Cardiovasc Med. 2018 Apr 7;20:40. doi: 10.1007/s11936-018-0635-x. Go to original source...
  38. Porta-Sánchez A, Gilbert C, Spears D, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: A systematic review. J Am Heart Assoc. 2017 Dec 7;6:12. pii: e007724. doi: 10.1161/JAHA.117.007724. Go to original source...
  39. Madias JE. Standard 12-lead electrocardiogram: A plausible patient monitoring tool for the emerging cardio-oncology programs. Am J Cardiol. 2017 Aug 1;120:e55-e56. doi: 10.1016/j.amjcard.2016.09.053. Go to original source...
  40. Grouthier V, Lebrun-Vignes B, Glazer AM, et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart. 2018 Nov 104;1859-1863. doi: 10.1136/heartjnl-2017-312934. Go to original source...
  41. Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation. Curr Cardiol Rep. 2016 Jun 18;52. doi: 10.1007/s11886-016-0730-0. Go to original source...
  42. Fradley MG, Viganego F, Kip K, et al. Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies. Open Heart. 2017 Dec 17;4:e000701. doi: 10.1136/openhrt-2017-000701. eCollection 2017. Go to original source...
  43. Mery B, Guichard JB, Guy JB, et al. Atrial fibrillation in cancer patients: Hindsight, insight and foresight. Int J Cardiol. 2017 Aug 1;240:196-202. doi: 10.1016/j.ijcard.2017.03.132. Go to original source...